Overview

Early add-on Vildagliptin in Patients With Type 2 Diabetes Inadequately Controlled by Metformin

Status:
Completed
Trial end date:
2015-10-22
Target enrollment:
Participant gender:
Summary
The purpose of this study was to observe change of HbA1c over time from baseline to month 12. The ultimate goal of this study was to provide a local reference value to the physicians & patients in the future when they consider initiating Vildagliptin and taking balance between efficacy, compliance, risk factors, convenience and medication cost.
Phase:
Phase 4
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Metformin
Vildagliptin